Page last updated: 2024-11-11

cgp 52608

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

CGP 52608: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5487510
CHEBI ID79994
SCHEMBL ID12186945
MeSH IDM0244027

Synonyms (8)

Synonym
cgp52608
87958-67-6
cgp 52608
1-methyl-3-[(z)-(4-oxo-3-prop-2-enyl-1,3-thiazolidin-2-ylidene)amino]thiourea
SCHEMBL12186945
CHEBI:79994
cgp 52608, >=98%, solid
hydrazinecarbothioamide, n-methyl-2-[4-oxo-3-(2-propen-1-yl)-2-thiazolidinylidene]-

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" RORalpha receptors are also expressed in MCF-7 breast cancer cells and the putative RORalpha agonist CPG-52608 inhibits MCF-7 cell growth but with a very different dose-response than melatonin."( Involvement of the mt1 melatonin receptor in human breast cancer.
Dai, J; Dong, C; Hill, SM; Kiefer, TL; Lai, L; Ram, PT; Yuan, L, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thiazolidinone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (33.33)18.2507
2000's15 (55.56)29.6817
2010's3 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]